3.74
+7.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NeOnc Technologies Holdings
From its filings with the US Securities and Exchange Commission
NeOnc Technologies Holdings is based in Calabasas, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NTHI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $39,990 and a net loss of $62.1m. At that date it held total assets of $2.8m and shareholders' equity of −$17.5m.
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain- malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
We have completed human testing in a Phase I clinical trial and are now conducting a Phase IIa trial with patients suffering from recurrent malignant glioma (WHO Grade III, IDH1 mutant, and WHO Grade IV, IDH1 mutant).
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Mar 2025
- Employees
- 5
- Website
- neonc.com ↗
- Head office
- 23975 PARK SORRENTO, CALABASAS, CA, 91302
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Amir HeshmatpourExecutive Chairman of the Board, President, Secretary, since 2023
- Dr. Thomas ChenChairman of the Board, Chief Executive Officer, Chief Scientific Officer, since 2023$212,000
- Mr. Keithly GarnettChief Financial Officer, since 2023$179,000
- Mr. Josh NemanChief Clinical Officer
- Mr. Bader AlmonawerLead Independent Director
- Dr. Ishwar PuriDirector
- Hon. Jim DelshadIndependent Director
- Dr. Steven GiannottaIndependent Director
- Dr. Victoria MedvecIndependent Director
- Ms. Laurie BermanInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NeOnc Technologies Holdings Inc employs 5 full-time employees focused on CNS disorder therapies.
- NeOnc's lead products NEO100 and NEO212 target brain cancer with innovative delivery methods.
- The company's clinical-stage focus on CNS disorders positions it for potential growth in the pharmaceutical sector.
Weaknesses
- NeOnc's small team of 5 employees may limit research and development capacity.
- The company's IPO on 26 March 2025 indicates limited market experience.
- NeOnc's two lead products are still in clinical stages without commercial approval.
Opportunities
- The growing demand for CNS disorder treatments presents a significant market opportunity.
- NeOnc's innovative intranasal delivery method for NEO100 could attract investor interest.
- The pharmaceutical industry's focus on CNS therapies offers potential partnerships.
Threats
- NeOnc faces competition from established pharmaceutical companies in CNS treatments.
- Regulatory hurdles for new CNS therapies could delay product approvals.
- The high cost of clinical trials for CNS disorders may strain the company's limited resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.